Phase 3 trial finds izalontamab brengitecan lengthened survival after esophageal cancer progressed
A phase 3 trial published on 12 November 2026 found that izalontamab brengitecan extended median survival to 9.79 months, compared with 7.20 months on physician-chosen chemotherapy, in 497 patients in China whose esophageal squamous cell cancer had progressed after…